Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy

2016 ◽  
Vol 26 (2) ◽  
pp. 225-233 ◽  
Author(s):  
Ching-Hua Lin ◽  
Ming-Chao Chen ◽  
Wei-Cheng Yang ◽  
Hsien-Yuan Lane
2018 ◽  
Vol 235 ◽  
pp. 169-175 ◽  
Author(s):  
Erika Martínez-Amorós ◽  
Ximena Goldberg ◽  
Verònica Gálvez ◽  
Aida de Arriba- Arnau ◽  
Virginia Soria ◽  
...  

2008 ◽  
Vol 24 (3) ◽  
pp. 224-228 ◽  
Author(s):  
Ertugrul Esel ◽  
Kader Kose ◽  
Yunus Hacimusalar ◽  
Saliha Ozsoy ◽  
Mustafa Kula ◽  
...  

2020 ◽  
Author(s):  
T Kroll ◽  
M Klingebiel ◽  
M Grözinger ◽  
M Matusch ◽  
A Novakovic ◽  
...  

1994 ◽  
Vol 165 (4) ◽  
pp. 506-509 ◽  
Author(s):  
Christopher F. Fear ◽  
Carl S. Littlejohns ◽  
Eryl Rouse ◽  
Paul McQuail

BackgroundThe induction agent propofol is known to reduce electroconvulsive therapy (ECT) seizure duration. It is assumed that outcome from depression is adversely affected by this agent. This study compares propofol and methohexitone as induction agents for ECT.MethodIn a prospective, randomised, double-blind study 20 subjects with major depressive disorder (DSM-III-R criteria) received propofol or methohexitone anaesthesia. The Hamilton Depression Rating Scale and Beck Depression Inventory were used to assess depression before therapy, at every third treatment, and at the end of therapy. Seizure duration was measured using the cuff technique.ResultsMean seizure durations (P < 0.01) and mean total seizure duration (P < 0.01) were shorter in the propofol group. There was no difference in outcome.ConclusionsUse of propofol may not adversely affect outcome from depression and it is not necessarily contraindicated as an induction agent for ECT. Our results should be interpreted cautiously, and larger studies are needed.


2013 ◽  
Vol 28 (8) ◽  
pp. 463-468 ◽  
Author(s):  
J.M. Azorin ◽  
A. Kaladjian ◽  
M. Adida ◽  
E. Fakra ◽  
R. Belzeaux ◽  
...  

AbstractObjectiveTo analyze the interface between borderline personality disorder (BPD) and bipolarity in depressed patients comorbid with BPD.MethodsAs part of National Multi-site Study of 493 consecutive DSM-IV major depressive patients evaluated in at least two semi-structured interviews 1 month apart, 19 (3.9%) had comorbid BPD (BPD+), whereas 474 (96.1%) did not manifest this comorbidity (BPD−).ResultsCompared to BPD (−), BPD (+) patients displayed higher rates of bipolar (BP) disorders and temperaments, an earlier age at onset with a family history of affective illness, more comorbidity, more stressors before the first episode which was more often depressive or mixed, as well as a greater number and severity of affective episodes.ConclusionsThe hypothesis which fitted at best our findings was to consider BPD as a contributory factor in the development of BP disorder, which could have favoured the progression from unipolar major depression to BP disorder. We could not however exclude that some features of BP disorder may have contributed to the development of BPD.


Sign in / Sign up

Export Citation Format

Share Document